Soligenix, Inc. (SNGX)
Largest Insider Buys in Sector
SNGX Stock Price History Chart
SNGX Stock Performance
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of …
Insider Activity of Soligenix, Inc.
Over the last 12 months, insiders at Soligenix, Inc. have bought $0 and sold $0 worth of Soligenix, Inc. stock.
On average, over the past 5 years, insiders at Soligenix, Inc. have bought $15,888 and sold $2,701 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $8,866 was made by SCHABER CHRISTOPHER J (CHAIRMAN, CEO AND PRESIDENT) on 2022‑05‑18.
List of Insider Buy and Sell Transactions, Soligenix, Inc.
| 2022-05-18 | CHAIRMAN, CEO AND PRESIDENT | 20,000 0.0466% | $0.44 | $8,866 | +23.81% | |||
| 2022-05-18 | SENIOR VICE PRESIDENT AND CMO | 8,000 0.021% | $0.50 | $4,000 | +23.81% | |||
| 2021-12-17 | CHAIRMAN, CEO AND PRESIDENT | 7,000 <0.0001% | $0.74 | $5,179 | -13.05% | |||
| 2021-12-15 | Senior Vice President and CFO | 1,000 <0.0001% | $0.70 | $700 | -10.86% | |||
| 2021-12-14 | Chairman, CEO and President | 10,000 0.0001% | $0.73 | $7,269 | -7.05% | |||
| 2021-12-14 | Senior Vice President and CFO | 10,000 0.0001% | $0.71 | $7,119 | -7.05% | |||
| 2021-05-14 | Sale | director | 3,000 <0.0001% | $0.90 | $2,701 | +1.43% | ||
| 2021-05-14 | director | 3,000 <0.0001% | $0.89 | $2,664 | +1.43% | |||
| 2019-11-19 | Chairman, CEO and President | 10,770 0.0544% | $0.93 | $10,016 | +92.63% | |||
| 2019-11-19 | director | 2,000 0.0101% | $0.93 | $1,850 | +92.63% | |||
| 2019-09-23 | director | 14,940 0.0003% | $0.93 | $13,870 | +95.33% | |||
| 2019-09-19 | director | 4,000 <0.0001% | $0.94 | $3,740 | +93.21% | |||
| 2019-04-22 | Chairman, CEO and President | 5,000 0.0001% | $0.72 | $3,577 | +47.89% | |||
| 2019-04-22 | director | 10,000 0.0002% | $0.73 | $7,274 | +47.89% | |||
| 2018-10-18 | Chairman, CEO and President | 8,700 0.0002% | $1.17 | $10,177 | -22.88% | |||
| 2018-10-17 | director | 170,000 0.0046% | $1.16 | $197,200 | -13.90% | |||
| 2018-08-22 | Chairman, CEO and President | 3,530 <0.0001% | $1.42 | $5,012 | -30.71% | |||
| 2017-11-29 | Sale | 16,416 0.0012% | $2.12 | $34,802 | -19.31% | |||
| 2017-11-29 | 293,510 0.0223% | $2.12 | $622,241 | -19.31% | ||||
| 2017-05-08 | Sale | 10 percent owner | 11,576 0.0009% | $2.54 | $29,403 | -16.86% |
Insider Historical Profitability
| CAVAZZA PAOLO | 10 percent owner | 54227816 2377.9749% | $3.54 | 3 | 0 | |
| CAVAZZA CLAUDIO | 10 percent owner | 54227816 2377.9749% | $3.54 | 3 | 0 | |
| BAM Management LLC | 10 percent owner | 21766092 954.4773% | $3.54 | 1 | 1 | |
| Pearson Mark E. | director | 2500000 109.6289% | $3.54 | 1 | 0 | |
| KANZER STEVE H | director | 1282203 56.2266% | $3.54 | 1 | 0 |